Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 4, 2016, Pages 543-549

  Papamichael, Konstantinos ^a,b   Van Stappen, Thomas ^b   Vande Casteele, Niels ^b   Gils, Ann ^b   Billiet, Thomas ^a   Tops, Sophie ^b   Claes, Karolien ^a   Van Assche, Gert ^a   Rutgeerts, Paul ^a   Vermeire, Severine ^a   Ferrante, Marc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Anti TNF Agent; Antibodies to Infliximab; Mucosal Healing; Ulcerative Colitis

Indexed keywords

INFLIXIMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BELGIUM; BLOOD SAMPLING; CLINICAL PRACTICE; COHORT ANALYSIS; COLON MUCOSA; CONTROLLED STUDY; ENDOSCOPY; FEMALE; HEALING; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SHORT TERM MUCOSAL HEALING; TERTIARY CARE CENTER; ULCERATIVE COLITIS; CHEMISTRY; COLITIS, ULCERATIVE; COLON; ENZYME LINKED IMMUNOSORBENT ASSAY; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; SERUM; TREATMENT OUTCOME;

ADULT; COLITIS, ULCERATIVE; COLON; ENDOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84960864810     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.11.014     Document Type: Article

References (44)

1. Billiet T., Rutgeerts P., Ferrante M., et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014, 14:75-101.
2. Sandborn W.J., Hanauer S., Van Assche G., et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014, 8:927-935.
3. Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol 2015, 50:43-52.
4. Levesque B.G., Sandborn W.J., Ruel J., et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015, 148:37-51.
5. Arias M.T., Vande Casteele N., Vermeire S., et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015, 13:531-538.
6. Ferrante M., Vermeire S., Fidder H., et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008, 2:219-225.
7. Laharie D., Filippi J., Roblin X., et al. Impact of mucosal healing on longterm outcomes in ulcerative colitis treated with infliximab: a multicentre experience. Aliment Pharmacol Ther 2013, 37:998-1004.
8. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
9. Vande Casteele N., Feagan B.G., Gils A., et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014, 16:378.
10. Vande Casteele N., Ferrante M., Van Assche G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015, 148:1320-1329.
11. Papamichael K., Gils A., Rutgeerts P., et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2015, 21:182-197.
12. Baert F., Vande Casteele N., Tops S., et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther 2014, 40:1324-1332.
13. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
14. Cornillie F., Hanauer S.B., Diamond R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014, 63:1721-1727.
15. Vaughn B.P., Martinez-Vazquez M., Patwardhan V.R., et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014, 20:1996-2003.
16. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
17. Colombel J.F., Sandborn W.J., Allez M., et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:423-431.
18. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
19. Roblin X., Marotte H., Rinaudo M., et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014, 12:80-84.
20. Reinisch W., Colombel J.F., Sandborn W.J., et al. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol 2015, 13:539-547.
21. Mazor Y., Almog R., Kopylov U., et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014, 40:620-628.
22. Paul S., Del Tedesco E., Marotte H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013, 19:2568-2576.
23. Adedokun O.J., Xu Z., Padgett L., et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis 2013, 19:2753-2762.
24. Adedokun O.J., Sandborn W.J., Feagan B.G., et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014, 147:1296-1307.
25. Vande Casteele N., Buurman D.J., Sturkenboom M.G., et al. Detection of infliximab concentrations and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012, 36:765-771.
26. Van Stappen T., Billiet T., Vande Casteele N., et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015, 21:2172-2177.
27. Imaeda H., Bamba S., Takahashi K., et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol 2014, 49:674-682.
28. Colombel J.F., Reinisch W., Mantzaris G.J., et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease-a SONIC post hoc analysis. Aliment Pharmacol Ther 2015, 41:734-746.
29. Yarur A.J., Rubin D.T. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015, 21:1709-1718.
30. Kobayashi T., Suzuki Y., Motoya S., et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis: results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol 2015, [Epub ahead of print].
31. Fasanmade A.A., Adedokun O.J., Ford J., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009, 65:1211-1228.
32. Ordas I., Feagan B.G., Sandborn W.J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:1079-1087.
33. Dotan I., Ron Y., Yanai H., et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014, 20:2247-2259.
34. Yarur A.J., Jain A., Sussman D.A., et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2016, 65:249-255.
35. Rosen M.J., Minar P., Vinks A.A. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther 2015, 41:1094-1103.
36. Gibson D.J., Heetun Z.S., Redmond C.E., et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015, 13:330-335.
37. Hendler S.A., Cohen B.L., Colombel J.F., et al. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis 2015, 9:266-275.
38. Brandse J.F., van den Brink G.R., Wildenberg M.E., et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015, 149:350-355.
39. Peyrin-Biroulet L., Reinisch W., Colombel J.F., et al. Clinical disease activity, Creactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014, 63:88-95.
40. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
41. Hindryckx P., Baert F., Hart A., et al. Clinical trials in ulcerative colitis: a historical perspective. J Crohns Colitis 2015, 9:580-588.
42. Tursi A., Elisei W., Picchio M., et al. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. Clin Res Hepatol Gastroenterol 2015, 39:107-113.
43. Vande Casteele N., Gils A. Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of Crohn's disease: avoiding failure while lowering costs?. Dig Dis Sci 2015, 60:2571-2573.
44. Vande Casteele N., Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol 2015, 55(Suppl 3):S39-S50.